Please assess the completion status of the following clinical trial:

Trial Title: The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* US Veterans~* type 2 diabetes mellitus (T2D) diagnosed within 3 years with good glycemic control on diet, metformin, or sulfonylurea agents or combinations of these agents (HbA1c ≤8.0%)~* T2D diagnosed ≥ 5 years prior to study enrollment~* Impaired glucose tolerance~Exclusion Criteria:~* T2D not meeting inclusion above criteria for duration of diabetes or HbA1c values~* known or suspected T1D (early onset age, low body mass index, lack of family history)~* TZD use in the prior 3 months~* prior regular use of insulin~* Creatinine \>2.0 mg/dl or other laboratory or clinical evidence of kidney disease~* anemia~* known active liver disease or hepatic enzyme elevation two-and-a half times above normal~* acute bacterial or viral illness or evidence of other active infection in the past 4 weeks~* stable or unstable angina or other major illness in the past 6 months~* Raynaud's disease or any rheumatic disease affecting fingers~* current regular use of anti-inflammatory medications or antioxidants, including over the counter medications and high dose salicylates (\>1 g/day);~* subjects receiving lipid lowering or anti-hypertension medications must be on stable doses for at least 2 months prior to participation.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Exenatide SC (Sub-study 1) (Type: EXPERIMENTAL): Study groups will be individuals with recent onset (\<3 years) or established (\>5 years) T2D. The plan is to achieve 40 complete studies of subcutaneous injection of exenatide BID (Byetta®, 5 or 10 µg) or identically looking Placebo SC for 10 days, separated by 14-day washout period. On the next day after each treatment phase, a single dose of the assigned medication will be injected just before a fat-enriched breakfast meal. A lunch meal of similar caloric and nutrient content will be administered 4 hours following the breakfast meal. Endothelial function will be measured just prior to the injection and every 2 hours during 8-hour post-breakfast period.
- Exenatide IV (Sub-study 2) (Type: EXPERIMENTAL): Study group will be individuals with recent onset (\<1 year) T2D on diet and impaired glucose tolerance. The plan is to achieve 35 complete studies. The intervention will include 3 randomly ordered visits with intravenous infusion of exenatide in the presence (v1) or absence (v2) of GLP-1 receptor inhibitor exendin-9, and a control test with Placebo IV without exendin-9 (v3). Endothelial function will be measured at baseline and 2 hours later during the final 15 minutes of the infusion cocktails. Study participants will remain fasting during the test visit (3 hours total).

Based on this trial design, predict the completion outcome and termination type (if applicable).